Effects of progestin-primed ovarian stimulation protocol plus clomiphene citrate in patients with low basal LH levels: a randomized controlled trial.

RCT OA: gold
📄 Open PDF View on PubMed View at publisher

Abstract

BackgroundInfertile patients with low basal luteinizing hormone (LH) levels have low oocyte retrieval rate, but whether progestin-primed ovarian stimulation (PPOS) protocol with clomiphene citrate (CC) could enhance oocyte retrieval rate in these patients remains unclear.MethodsThis prospective randomized controlled trial was performed between January 2018 and February 2021, included 230 infertile patients with low basal LH levels (LH < 2.27 mIU/mL). In study group, 115 patients received human menopausal gonadotropin (hMG) 150 or 225 IU/d + CC 50 mg/d + medroxyprogesterone acetate (MPA) 10 mg/d from the third day of menstruation. In control group, 115 patients received hMG 150 or 225 IU/d + MPA 10 mg/d from the third day of menstruation. Viable embryos were cryopreserved for later transfer. The primary outcome measure was the oocyte retrieval rate.ResultsCC contributed to LH secretion. The hMG+MPA+CC group showed a decreased oocyte retrieval rate (0.71 ± 0.22 vs. 0.76 ± 0.18, mean difference (MD) -0.06 (-0.11 to -0.01); P = 0.043) and a decreased number of cryopreserved embryos (2.89 ± 2.43 vs. 3.90 ± 2.39, MD -0.89 (-1.50 to -0.28); FDR-P = 0.035). Two groups had similar number of retrieved oocytes (8.83 ± 5.41 vs. 10.69 ± 5.85, MD -0.99 (-2.27 to 0.29); FDR-P = 0.213) and oocyte utilization rate (0.40 ± 0.25 vs. 0.46 ± 0.24, MD -0.07 (-0.14 to -0.01); FDR-P = 0.084). Two groups had comparable cumulative clinical pregnancy rates (61.05% vs. 77.67%, hazard ratio (HR) 0.74 (0.53 to 1.06); P = 0.101; FDR-P = 0.214) and cumulative live birth rates (53.68% vs. 66.02%, HR 0.77 (0.53 to 1.13); P = 0.183; FDR-P = 0.214).ConclusionsCC contributed to LH secretion, but PPOS protocol with CC resulted in a lower oocyte retrieval rate in patients with low basal LH levels. PPOS protocol with CC should be used cautiously in these patients.Trial registrationChiCTR number: ChiCTR1800014440. URL: https://www.chictr.org.cn/showproj.html?proj=24573 . Date of registration: 2018/01/13. Date of enrollment of the first subject: 2018/1/17.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 42
progestin progesterone progesterone clomiphene citrate estradiol medroxyprogesterone acetate testosterone estradiol progesterone estradiol triptorelin hormone cresol red clomiphene diethylcarbamazine citrate progesterone progesterone progesterone testosterone estradiol testosterone testosterone testosterone estradiol estrogen clomiphene diethylcarbamazine citrate clomiphene diethylcarbamazine citrate hormone clomiphene diethylcarbamazine citrate medroxyprogesterone acetate progestin clomiphene diethylcarbamazine citrate progestin clomiphene diethylcarbamazine citrate medroxyprogesterone acetate
organisms 4
promicromonospora sp. cc 0387 rattus sp. humans human

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
scilite
last seen: 2026-11-15T10:16:09.319260+00:00